Stage III MSS patients without adjuvant chemotherapy that lacked versican expression had a significantly worse survival than those with versican expression in the periphery of the tumor, while this difference was not observed among stage III patients who received adjuvant chemotherapy (Fig. 3e,f). The gene discussed is VCAN; the disease is neoplasm.